Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EEF2K | O00418 | 2/20 | 0.35 |
| ▸ | EEF2 | P13639 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | PLK4 | O00444 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | ITK | Q08881 | 1/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11999065 | 0.91 | CYP1A2 (0.40) | MEN1KMT2ACYP1A2POLBCYP3A4 | |
| SCHEMBL5817318 | 0.87 | ABCB11 (0.46) | — | |
| SCHEMBL5295972 | 0.87 | ABCB11 (0.46) | — | |
| SCHEMBL5297847 | 0.87 | ABCB11 (0.46) | — | |
| SCHEMBL5298450 | 0.87 | ABCB11 (0.46) | — | |
| SCHEMBL5301214 | 0.87 | ABCB11 (0.46) | — | |
| SCHEMBL5295433 | 0.87 | ABCB11 (0.46) | — | |
| SCHEMBL5304009 | 0.87 | ABCB11 (0.46) | — | |
| SCHEMBL5813633 | 0.87 | ABCB11 (0.46) | — | |
| SCHEMBL5307703 | 0.87 | ABCB11 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8956445-B2 | High stability diionic liquid salts | SIGMA-ALDRICH CO. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8956445-B2 | High stability diionic liquid salts | SIGMA-ALDRICH CO. (US) | 2015-02-17 | — | — | US | disclosed |
| US-20120211696-A1 | HIGH STABILITY DIIONIC LIQUID SALTS | SIGMA-ALDRICH CO. LLC (US) | 2012-08-23 | — | — | US | disclosed |
| US-8168830-B2 | use of these novel ionic liquids having bis-cation or bis-anion separated by bridging group as the stationary phase in a gas chromatographic column | SIGMA-ALDRICH CO. LLC (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168830-B2 | use of these novel ionic liquids having bis-cation or bis-anion separated by bridging group as the stationary phase in a gas chromatographic column | SIGMA-ALDRICH CO. LLC (US) | 2012-05-01 | — | — | US | disclosed |
| US-20080027231-A1 | High stability diionic liquid salts | SIGMA-ALDRICH CO. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027231-A1 | High stability diionic liquid salts | SIGMA-ALDRICH CO. (US) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027231-A1 | High stability diionic liquid salts | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HDHD5, DAD1 | EEF2K 4303/4885EEF2 3892/4885MEN1 3166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.